ALIM - Alimera granted pricing reimbursement in France for eye inflammation Iluvien injection
- Alimera Sciences ( NASDAQ: ALIM ) on Friday said it would launch its Iluvien injection for the treatment of uveitis, a type of eye inflammation, in France through its distribution partner Horus Pharma.
- ALIM said Horus had been granted pricing and reimbursement approval for Iluvien for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Economics Committee for Health Products.
- Alimera ( ALIM ) did not disclose the pricing determination for Iluvien.
- Earlier in July, ALIM got Italian regulatory approval and was granted pricing and reimbursement for Iluvien for the same indication.
- ALIM stock closed +0.8% at $5.33 on Thursday.
For further details see:
Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection